|
EXEL | Exelixis, Inc. |
|
|
EXEL | Exelixis, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.17 |
| Leverage | 23.48% |
| Market Cap | $ 12.9B |
| PE | 19.30 |
| Dividend Yield | 0.00% |
| Profit | $ 667.9m |
| Margin | 29.71% |
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.